R&D biotech dedicated to pain-free, safe, innovative tattoo removal, providing a clean slate to those with tattoo regrets. Investment opportunities available.
https://t.co/aK5q9T9p4X has been updated to reflect our current status. We’re gearing up to publish our phase 1 pilot and are fundraising to begin phase 2. If our research goes as planned, we’re working toward identifying a candidate drug/molecule/technique in phase 3 (2020).
EXtatin will soon close off our Phase 1 pilot to enter Phase 2. We do not have a product, aiming to discover of a testable technique in 2020. If successful, we'll begin safety studies. Feel free to contact us at [email protected] with your science/investor interests. #EXtatin.com